Good day, and thank you for standing by. Welcome to the Q4 2022 IRIDEX Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Tripp Bailey Investor Relations. Thank you. Thank you all for participating in today's call. Joining me are David Bruce, CEO, and Fuad Ahmad, Interim CFO. Earlier today, IRIDEX released financial results for the quarter ended December 31st, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call are not statements of historical fact, including but not limited to statements concerning our strategic goals and priorities, product development matters, sales trends, and the markets in which we operate. All forward-looking statements are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place reliance on these statements. For a discussion on the risks and uncertainties associated with our business, please see our most recent Form 10-K and Form 10-Q filed with the SEC. IRIDEX disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, March 9th, 2023. With that, I'll turn the call over to Dave. Thank you, Tripp. Good afternoon, and thank you all for joining us. Today, I'll provide updates on our recent business progress and discuss our 2023 outlook. Fuad will provide details of the 2022 Q4 and full-year financial results. We'll open the call for questions. As we pre-announced on January 10, for the full year 2022, we generated revenue in line with our guidance of $57 million, representing an increase of 6% compared to 2021. Beyond the financial results, 2022 was highly productive for IRIDEX. We achieved regulatory clearance to market and sell the Cyclo G6 platform in China, introduced Sweep Management Software for the Cyclo G6, maintained a strong presence at Glaucoma Society meetings, and published the two-part expert consensus to raise awareness of the clinical benefits of MicroPulse TLT. Despite a soft first half to the year from COVID-19 and international challenges of dollar strength and inflation, these activities meaningfully advanced G6 adoption and G6 probe growth in the second half of 2022, and we continue to experience solid growth this quarter to date. We received FDA clearance for the next generation IRIDEX PASCAL scanning laser platform in November and are today announcing clearance of the IRIDEX 532 and 577 single-spot laser platform received in February. We've already begun the U.S. launch for PASCAL and will begin the single-spot platform launch at mid-year. We expect all these achievements to build momentum for our business in 2023. Turning to the Q4, revenue totaled $15.2 million, in line with the prior year period, driven by growth from the Cyclo G6 product family, U.S. retina sales, and other revenue being offset by declines in some retina products internationally. We also reduced our cash used in operations by half to under $1 million in the quarter. Looking closer at the glaucoma business, Cyclo G6 revenue increased by 9% year-over-year to $4.2 million. In the quarter, we achieved record international G6 probe unit sales and sold a worldwide total of 16,400 probes, representing growth of 8% compared to the Q4 of 2021. G6 system sales decreased slightly compared to the prior Q4, but results were at the midpoint of our overall annual guidance. We see significant opportunities to increase G6 probe volume and adoption by staying focused on four key initiatives. First, continuing our advanced physician education, keying on proper dosing and broader patient selection criteria. Second, targeting comprehensive ophthalmologists who see the most moderate stage preincisional patients. Third, adding users at surgery centers that already have G6 systems. Fourth, expanding clinical evidence supporting adoption of MicroPulse TLT. The main components of our education strategy are peer-to-peer discussions on dosing recommendations based on clinical study evidence and sharing updates on MicroPulse TLT use on a broader patient population. Earlier in the glaucoma treatment continuum. At the AGS, just completed in Austin, Texas, Dr. Syril Dorairaj presented his early results from a prospective randomized dose escalation study demonstrating 31%-44% intraocular pressure reductions with greater treatment efficacy resulting from slower probe sweep speeds while still providing the same consistently excellent safety profile. It's becoming clear that the key to consistently high IOP reduction is proper sweep speeds, and that this technique maintains the very benign safety profile. To facilitate excellent treatment technique, we launched and promoted our Sweep Management Software systems software upgrade. This software helps guide users to select and execute proper sweep speeds during treatments according to best practices developed by our clinical consensus panel. It's working. Users are reporting this helps reduce variability of technique and helps them deliver more consistently strong results to meet their outcomes expectations. The next component of our growth strategy is to increase awareness of the benefits of MicroPulse TLT earlier in the glaucoma treatment continuum as an effective pre-incisional intervention. About 50% of the 2022 proctored cases supported by our field team were pre-incisional patients treated by both glaucoma specialists and increasingly with targeted comprehensive ophthalmologists who typically diagnose and treat patients with earlier stages of glaucoma. This targeted cohort of clinicians and patients has the potential to meaningfully expand G6 penetration in the continuum of glaucoma care. Internationally, we initiated the G6 launch in China in the second half of last year alongside our distribution partners with 15 key opinion leader pilot sites and approximately 120 patients. While China's COVID policy lockdowns in 2022 slowed the initial adoption ramp, patient flow is increasing again, we believe this can drive growth in 2023. Last year, we increased our international commercial team to provide more expert resources in support of our distribution partners and customers. Finally, we have great confidence. We have the right probe design and clinical proof of efficacious and very safe dosing guidance executed through user software supporting proper treatment protocols. We believe we have a stable procedure ready to design and launch a larger scale multi-center prospective trial. The study will target demonstrating the safety and substantial effectiveness of MicroPulse TLT for moderate stage glaucoma patients. Active discussions on proper study design and protocols are underway with key opinion leaders. Once we've determined the optimal protocols for the study, we can begin to recruit participating centers. We are making this investment in 2023 and hope to begin enrolling patients in the study by year-end. We have high conviction in our ability to grow the glaucoma business over the long term. We're excited to provide this on a larger scale and ultimately capture a substantial role in the continuum of care for glaucoma sufferers. Altogether, as we look ahead to 2023, we expect to increase the growth rate of our glaucoma business. We expect probe revenue growth of 9%-12% compared to 2022. We expect to sell 65,000-67,000 probes and grow the installed base by 225-250 glaucoma laser systems. Now turning to our retina business. For the fiscal year 2022, product revenue increased by 2% to $31.7 million compared to 2021, despite some softness in the international markets leading to a decrease of 11% in the Q4 compared to the prior year period. On our last call, we announced we had received U.S. FDA clearance for our new PASCAL laser scanning platform. We began shipments to U.S. customers in the Q4, and we anticipate regulatory filings and approvals internationally throughout 2023. The new IRIDEX PASCAL platform offers the ultimate combination of the leading pattern scanning engine, Endpoint Management Technology, Pattern Scanning Laser Trabeculoplasty, which is a glaucoma treatment for early stage patients. Now with IRIDEX's proven MicroPulse technology, it provides physicians with expanded treatment capabilities in an integrated system with one half the footprint of the prior platform. Today, we're pleased to announce that we received FDA clearance in February for our single spot platform consisting of the IRIDEX 532 green laser and the IRIDEX 577 yellow laser. We'll share more details as we launch them in the U.S. around mid-year. We believe both updated laser platforms can drive replacement cycles for the significant installed base of older equipment reaching end of life. The improvements we've made not only include technology updates that will produce clinical benefits, but also provide manufacturing efficiencies that will translate to pricing flexibility for share gains or improved margins. Our investments over the last couple of years have resulted in material improvements to our retina business, and it's now operating from a significantly stronger competitive position in both product and sales channel potential. Now I'd like to turn the call over to Fuad. Good afternoon, everyone, and thank you for joining us today. I would like to begin by reviewing our financial performance for the Q4 and full year fiscal 2022. Starting with revenue. Our total revenue for the Q4 was $50.2 million, which was in line with the Q4 of last year. Our total revenue for 2022 increased by 6% to $57 million, compared to $53.9 million in 2021. Moving on to product revenues. The overall revenue from the Cyclo G6 product family in the Q4 was $4.2 million, up 9% compared to the same period in 2021. We are pleased to report that we sold a quarterly record 16,400 Cyclo G6 probes in the Q4, an increase of 8% from the prior period, and an increase of 20% quarter-over-quarter. We sold 79 Cyclo G6 systems in the quarter compared to 90 in the prior period. Total glaucoma product revenue for 2022 was $14.7 million, up 5% from 2021. Our retina product revenue in the Q4 was $8.1 million, a decrease of 11% compared to the prior period. For the full year 2022, our retina product revenue was $31.7 million, up 2% compared to 2021. Other revenue, which includes royalties, services and other legacy products, increased 26% to $2.9 million in the Q4, compared to the same period in 2021. For the full year 2022, other revenue grew 20% to $10.6 million compared to $8.8 million in 2021 on higher service, royalty, top-line distribution and legacy product revenue. Our gross profit for the Q4 of 2022 increased to $6.7 million, up 11% for the same period last year. Gross margin was 43.9% compared to 39.3% in the Q4 of 2021 on revenue mix that favored U.S. revenue. Gross profit for the full year was $25.4 million, up 11% from the prior year. Gross margin was 44.5% in 2022 compared to 42.3% gross margin during the same period last year. Operating expenses for the Q4 were $8.1 million compared to $8.4 million in the same period of the prior year. Total operating expenses for 2022 were $32.9 million compared to $30.4 million in 2021. Our net loss in the Q4 was $1.1 million, or a net loss of $0.07 per share compared to a net loss of $2.4 million or $0.15 per share for the same period in 2021. For the full year, we recorded a net loss of $7.5 million or $0.47 per share compared to a net loss of $4.2 million or $0.34 per share in 2021. Cash and cash equivalents as of December 31st, 2022 totaled $13.9 million. Cash used in the operation was down $900,000 in the Q4 while the total cash reduction in the quarter was only $2 million. The cash reduction during the year of $10 million included approximately $3.5 million increase in inventory and related pre-orders to mitigate supply chain issues. We expect such inventory to substantially unwind over the course of 2023. I will now provide our guidance for the full year of fiscal 2023. We anticipate Cyclo G6 probe unit sales of 65,000-67,000, which represents a growth of 9%-12% over the prior year. We expect to expand the Cyclo G6 systems install base by 225-250 units. Total revenue for the year is expected to be $57 million-$59 million. Please note that the full year 2023 total revenue guidance represents a growth of approximately 3%-6% after adjusting for an approximate $1.5 million reduction of other revenue royalty income resulting from the expiration of licensed patents. Implicit in our guidance for fiscal 2023 is full recovery from any lingering COVID-19 related pressures. Currency fluctuations, inflation and supply chain may continue to represent headwinds, albeit manageable. We are confident in our ability to address such issues and continue to execute on our core strategy centered around increasing growth in our glaucoma treatment adoption and rolling out our new retina platform. I will now turn the call over to the operator for any questions. Operator? Thank you. As a reminder, to ask a question, please press star 11 on your telephone and wait for your name to be announced. To withdraw your question, please press star 11 again. Our first question comes from Scott Henry with ROTH Capital. You may proceed. Thank you. Good afternoon. I just had a couple questions, largely on the modeling front. First, any thoughts on how we should expect the cadence of the year to go as far as revenues? Any guidance or should we expect historical trends? Hi Scott, how are you? I think it's shaping up to be more of a typical. As you know, we're not linear. We have typically see. Strongest in the Q4, some softness in the Q3, maybe the second strongest is the Q2. That's from where we sit today, I don't see that changing dramatically. Okay. Should we expect operating expenses to be similar in 2023 as in 2022? Would gross margins be similar, or might we get, you know, a little bit of gross margin expansion? How should we think about that? I think let me address the gross margin first. I think we should see some marginal, you know, expansion of gross margin in 2023 relative to 2022. I think 2022 was still a period in which we were, you know, we had supply chain issues, and we were making payments in advance and sometimes paying a premium for some parts. I think that should subside in 2023. We should expect some expansion. You know, we're not gonna see the expansion that, you know, we were hoping for in 2022, just given there's still some lingering supply chain issues that we have to deal with. I think overall, you should see the expansion. I think as you know, a lot of our gross margin depends on both geographic mix as well as the product mix. You know, with the glaucoma becoming bigger part of the business or increasingly bigger part of the business, you know, we should see naturally gross margins to expand from that as well. Yeah, I think the answer to your question, simple answer is we should see some expansion in 23. As for the OpEx, I think for most part, we expect R&D to G&A to kind of remain flat. We do expect sales and marketing, where our clinical spend is to grow. I think we are going to be investing, more dollars into the clinical spend with a view towards, growing the adoption rate, and that's, you know, that's been our, mantra for our last couple of years, and it's expected to continue. Okay. should we expect- you know, we're not talking about a major- Okay. In the new PASCAL product, should that grow revenues for that line, or is it more of a substitutive extension? I think there's two elements to that. One is it's a more capable system and a smaller footprint. A lot of institutions who may not have bought it in the past because of the size now could be attracted and it's got MicroPulse capability as well, which it never had in the past. I think that all expands the pool. I think as a new platform, it may be the catalyst for some older sites. We have a significant percentage of PASCAL systems in the installed base that are old and some even past the end of service date, meaning if they wanted to send it in for repairs, we essentially we can't do it. That can potentially trigger somewhat of a replacement cycle. We look for some modest growth because of that piece. I think internationally still remains to be seen because we have to roll out approvals. It's primarily a U.S. phenomenon for the early part and as a percentage for most of the year 2023. Okay. Dave, a follow-up question and the last question. I mean, it sounds like 2023's going to look a lot like 2022. A little bit more revenues, a little bit more expenses gonna lose between, you know, a little more than $5 million in the year, pulling out stock comp. The question is, I mean, you're kind of at a fork in the road. Either you grow faster to get profitable or you cut expenses to get profitable. I mean, you're not losing a lot of money, but you're still losing money. You know, of those two pathways, I mean, it sounds like your idea is to invest in the clinic and try to get the top line growing faster. I just wanna give you an opportunity to perhaps, shed some light on what direction you'd like to take the company in. We think that there is a very large growth opportunity in glaucoma. We view the 22 activities as really rebuilding the foundation there and proving out the elements that we believed were in place. I think by investing in the broader, larger clinical study, that we will prove that out further and create a real adoption evidence base that can drive us from, say, early adopters or use at the margin when other things aren't working into the mainstream. That's just a very large opportunity. We're focused on that big growth piece. The decision to maintain the level of investment in sales and marketing and clinical is really driven by that. We do see a tailwind from unwinding the inventory builds and prepaids, because we think the supply chain can soften up and get back toward normal in 2023. You know, we were up $3.5 million in cash usage of 2022 because of that, and if we unwind that turns into a cash tailwind. A comparable usage of cash with a, with a tailwind of cash coming from the balance sheet puts us still with a substantial amount of cash and the runway to execute that growth trajectory. Okay, great. Thank you for the color, and thank you for taking the questions. Thank you. Thank you. Our next question comes from Tom Stephan with Stifel. You may proceed. Great. Hey, guys. Thanks for the questions. I'll start with the G6 probe growth guidance of 9%-12%. Dave, can you just talk a bit about the different dynamics at play between the U.S. and the OUS? I know in the OUS there's maybe been some volatility, but just for 2023, how are you thinking about kinda growth between each region? Hi, Tom. Yes. We do anticipate, I'll say, continued volatility in the international space. As much as we're focused on very specific activities to drive that growth and working with our distribution partners, it can still ebb and flow. We don't have direct contact to sell into customers and so we maybe are a little bit more conservative on how much we can grow internationally. Domestically, we're starting to see the impacts of renewed confidence, I'll say, or broader confidence given our treatment parameters, as well as coupling that with a Sweep Management Software methodology to assure that the intended techniques are actually followed through. You and I have talked about the challenges or opportunities to standardize that treatment. We think that we can be a little stronger in the U.S. compared to OUS in terms of probe growth. As I commented, we're starting to see that follow through here at least Q1 to date. You know, we're encouraged that, that we're gonna accomplish that. Got it. That's helpful. Dave, if I can push you a bit, just looking at the model, believe it implies flat utilization year-over-year in 2023. Again, OUS was challenging in 2022 as well. The comp isn't overly difficult on that front. I guess big picture, you know, what gives you confidence you can reaccelerate growth in the glaucoma business more broadly? You gave the four key initiatives, which make perfect sense, but I guess just what really gets this going again, and maybe what's the timing of when we'll start to see those signs trickle through in the numbers? Thanks for that. I think we see the signs that it's working in the sense that when people select the right treatment parameters and then execute those, that they are pleased with the results, and they're substantial. The study that I was referring to that was presented, at least the early results presented at the American Glaucoma Society, 30% and 40% IOP reductions are at the top end of what can be achieved with other technologies. We're really pleased that we can do that with a non-incisional procedure and get the durability, which when you get those high IOP reductions in a 3-6 month period, it tends to carry on for durability. We'll see what the particular study data demonstrates, but we expect that to bear out. As you get those kinds of results in the hands of users, they tend to gain confidence and start to select a broader set of patients. That's what we're really focusing on for 2023. Our sales reps are very focused on targets and taking those targets down that pathway of proctored cases and recognizing the results on a representative sample of their patients. As you look at the opportunity in the space, there's just a dramatically large number of potential procedures if we can achieve that adoption in the moderate stage preincisional patients. I've talked about the analogy with SLT, the early stage laser glaucoma treatment that's been around for 20 years and is clinically mature and has penetrated about 20% of the mild stage patients in the U.S. That's the opportunity we're pursuing in about 2 million moderate stage patients. It'll take time, but if you have efficacy, you have safety, and you have a way to demonstrate to clinicians that they can achieve that in their hands, you know, we're very confident that will drive adoption. You know, the challenge is what rate, you know, to a certain extent that's part of the frustration. At the same time, you know, medical device adoption is always well considered, I'd say, by the mainstream community, and it, and it takes a little bit longer. When you get that critical mass, the growth rates go up. You know, we're not trying to predict where that critical mass point and increasing growth rate occurs. We do our guidance based on what we think we can execute through the team, given the current situation. I know that doesn't you know identify exactly where that knee occurs and it really starts to accelerate. I think all the pieces are in place to get us there. No, that makes perfect sense. Thanks for that, Dave. Just to pivot to retina for my last question. Might be some unknowns around the G6 ASPs, but to reach the midpoint of your guidance, I'm arriving at roughly flat retina growth. But you do have a lot of new products coming into the field. I guess, Fuad, am I thinking about that growth correctly? Dave, can you just talk a bit about kind of what headwinds might be suppressing, you know, potential positive growth in the retina business? Thanks. I mean, I think retina, you know, we anticipate the retina to grow, but it's gonna, you know, generally grow with markets somewhere around 3%-4%. I think there's opportunity for growth further because of the rollout of new products, you know, especially the Gen M on the PASCAL side, as well as the rollout of the new platform. I think there is an opportunity there for growth in retina as well. I think for us, when we think about retina, we think about at least preserving market growth rate which, you know, is at least 3%, could be a little higher. Know that, I think, on the overall revenue, I think one of the things you should be, looking at is that we did, as we mentioned in our, prepared remarks as well as in the earnings, release itself, that we have about $1.5 million of headwind, on some royalty income due to some expiring, patents, that will, happen over the course of the year. I think we'll, it'll, it'll emerge, it'll manifest itself in the second half of next year. You might, you know, you might wanna, make a, adjustment to your model, for that. You have to subtract that. It comes from other revenue. If you look at the overall growth rate, I think we're still, you know, mid to low to mid double digit for glaucoma and about 3% growth on the retina piece. Just kinda as you work through your models. In terms of, I think the last question you asked is the headwinds, I think it's kinda uncertainty. you know, we had headwinds on the for stronger dollar for most of fiscal 2022. That impacted the OUS sales, not just for retina, but also on the glaucoma side. I think that's still a little bit of headwind going into 2023. you know, we'll have to manage that. I think that I see as the biggest headwind for the business, not just the retina piece. We have been generally successful on the supply chain side. We've, you know, I think it's safe to say that we haven't missed a lot of revenue due to shortages. The team has done a good job here, but that still, you know, still casts a little pall over over the business. I think for most part, I think at this point, I guess the currency and some inflationary risk that we're all dealing with probably is the biggest factor into 2023. Got it. Very helpful. Thanks. Mm-hmm. Thank you. This concludes the Q&A session. I'd now like to turn the call back over to Dave Bruce for any closing remarks. Thank you, operator. Thank you all for joining us. We're looking forward to a strong 2023 performance and reporting to you in upcoming quarterly results. Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect.